In April 2026, Canada became the first G7 country to approve a generic version of semaglutide for adults with type 2 diabetes

Mechanism of Action Stimulates melanocortin receptors in the central nervous system Triggers dopaminergic pathways that control sexual desire and arousal Enhances readiness for intimacy without needing sexual stimulation beforehand Intranasal delivery bypasses the digestive tract for fast systemic absorption Onset of action: approximately 1530 minutes Duration of effects: typically 48 hours Clinical Indications This nasal spray is used to treat or support: Hypoactive Sexual Desire Disorder (HSDD) in pre- and postmenopausal women Sexual arousal difficulties in men and women Erectile dysfunction (ED) with a psychological or neurogenic basis Libido decline related to aging, stress, SSRIs, or hormonal therapy Performance anxiety and intimacy issues in otherwise healthy individuals PT-141 nasal spray is especially useful for individuals who prefer non-injectable options and desire discreet, self-directed use

, based on your unique metabolic profile: Metabolic Markers: We may review your full lab panel, including A1C and insulin sensitivity
BPC-157 is a 15-residue, 1419.53 g/mol pentadecapeptide from human gastric juice whose literature centres on local angiogenic signalling via VEGFR2 and on nitric oxide pathway modulation
Protect the vial from excessive heat, strong light, and freezing to maintain stability
The primary metabolites of cholesterol in the liver that aid in the absorption of lipids, nutrients, and lipophilic vitamins are bile acids, which are produced by the rate-limiting enzyme cholesterol 7-alpha-hydroxylase (CYP7A1) (90, 91), and also the energy metabolism, regulation of lipids and glucose (92, 93)